TP53 and metastatic neoplasm: When patients with metastatic disease at diagnosis were excluded from the analysis, most patients with a TP53 mutant tumor had favorable event-free survival, although with the current median follow-up (46 mo, range 3–103 mo), it did not reach statistical significance (Figure 1B, left graph; Table S1).